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We evaluated the immunohistochemical expression of ret finger protein (RFP) along 
with conventional immunohistochemical markers in endometrioid and serous carcino-
mas of the endometrium. 
A total of 124 endometrial carcinoma cases (24 grade 1 endometrioid, 60 grade 3 en-
dometrioid, 40 serous) were retrieved from pathology archives. Tissue microarrays were 
constructed. The expression of RFP, WT1, ER, PR, p53 and p16 was examined im-
munohistochemically. Sensitivity, specificity, area under the receiver operating charac-
teristic (ROC) curve, κ statistic for interobserver reproducibility, Kruskal-Wallis test, 
Mann-Whitney U test and Fisher’s exact tests were performed for statistical analyses. 
The mean RFP score was 1.54 in grade 1 endometrioid, 4.31 in grade 3 endometrioid, 
and 6.31 in serous carcinomas (p < 0.001). Overall, RFP scores were higher both in 
serous and grade 3 endometrioid carcinoma (p > 0.05), and significantly lower in grade 
1 endometrioid carcinoma (p < 0.05). p16 and p53 staining patterns were able to 
differentiate between high-grade endometrioid and serous carcinoma (p < 0.001). ER, 
PR and WT-1 did not reach statistical significance for subtyping. The κ values of the 
general agreement between the observers were 0.737 and 0.727 for endometrioid and 
serous carcinomas respectively (p < 0.001). 
Diffuse p53 and p16 staining provides the most sensitive and specific immunomarkers 
for differentiating high-grade endometrioid and serous carcinomas.
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Introduction
Endometrial cancer is the fourth most common ma-
lignancy among women in the US and the fifth lead-
ing cause of cancer-related deaths in women in western 
countries [1]. Endometrial carcinoma is a morphologi-
cally heterogeneous disease with several histotypes and 
grades. These histotypes, when taken together with 
their clinical features, can be divided into two major 
categories. Type 1 endometrial carcinomas are histo-
logically low-grade endometrioid type adenocarcino-
mas (EAC). They have a good prognosis, are associated 
with unopposed estrogen exposure, and are related to 
endometrial hyperplasia [2, 3]. Type 2 endometrial 
carcinomas (uterine serous carcinomas [USC], clear 
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cell carcinomas [CCC] and carcinosarcomas) are his-
tologically high-grade lesions, of non-endometrioid 
morphology, unrelated to estrogen excess, and have 
a less favorable prognosis than type 1 carcinomas [4]. 
Type 1 carcinomas are usually diagnosed in the ear-
lier stages, and their management is less drastic [5]. 
Type 2 cancers, although less frequently seen, account 
for a disproportionately high number of deaths when 
compared to type 1 cancers [6, 7]. 
The molecular background of these two groups is 
dissimilar [2, 8]. Integrated genomic and proteomic 
analysis of endometrial carcinomas can reveal totally 
different subtype groupings and may shed light on 
future classifications [9]. In daily practice, to address 
this problem of differentiating the two types of endo-
metrial malignancy, a large number of immunomark-
ers have been proposed and evaluated [10, 11, 12]. 
Ret finger protein (RFP) was originally identified as 
a fusion protein with RET receptor tyrosine kinase and 
exhibits transcriptional repressive activity [13]. This 
protein belongs to the large B-box RING finger pro-
tein family, which has more than 200 members. RFP 
is expressed in several tumor cell lines of rodents and 
humans [13 ], but the exact function of this protein in 
tumors is not clear. A previous study has shown that 
RFP expression might be helpful in differentiating se-
rous carcinomas and (type 1) endometrial carcinomas 
[14]. Immunohistochemical expression of RFP may be 
associated with adverse outcomes – in terms of overall 
survival and progression-free survival – in endometrial 
cancer patients, irrespective of histological type [15].
This study aims to determine and compare the im-
munohistochemical expression of RFP with conven-
tional immunohistochemical markers (p16, WT1, 
p53, PR, ER) in grade 1 and grade 3 EAC and USC 
of the endometrium. The hypothesis is that RFP may 
aid in the distinction of high-grade endometrial car-
cinomas of endometrioid type from serous carcino-
mas of the endometrium. 
Material and methods
Case selection and tissue microarray 
construction
This study was performed retrospectively on sam-
ples of hysterectomy specimens, dating from Janu-
ary 2000 to December 2010, retrieved from the pa-
thology archives of three institutions (Department 
of Pathology, Hacettepe University; Department of 
Pathology, Ministry of Health Etlik Zubeyde Hanim 
Women’s Health Education and Research Hospital; 
Department of Pathology, Baskent University). 
Cases with a diagnosis of high-grade endometrial 
EAC (grade 3) and USC were selected, as well as 24 
cases of grade 1 endometrial EAC from the archives of 
Hacettepe University Hospital. In the previous study 
[14], serous carcinomas were positive and low-grade 
endometrioid carcinomas were negative with RFP, so 
we selected grade 1 EAC cases to compare the RFP 
expression with grade 3 EAC. All cases were reeval-
uated and classified according to the World Health 
Organization (WHO) system, and a tumor grade 
was given based on the FIGO grading system. A to-
tal of 124 endometrial carcinoma cases (60 grade 3 
EAC, 40 USC, 24 grade 1 EAC) were selected by five 
experienced gynecopathologists from the 3 institu-
tions. Representative slides and paraffin blocks were 
chosen and tissue microarrays were constructed. The 
pathologists also independently reviewed immuno-
histochemically stained slides, assessing scores for the 
expression of each immunohistochemical marker and 
noting the final diagnosis for each case. The patients’ 
ages, the presence or absence of ovarian involvement 
by carcinoma, and FIGO stages were also noted.
Paraffin-embedded tissues from 124 endometrial 
adenocarcinomas and control tissues were used to 
construct a tissue microarray. Biopsies from non-neo-
plastic endometrial tissues from separate cases of pa-
tients were used as normal controls. Briefly, after the 
morphologically representative region on the blocks 
was chosen (donor block), a core tissue biopsy of 0.6 
mm was punched and transferred to the recipient 
block (receiver block). To overcome tumor heteroge-
neity and loss of tissue, three cores were selected from 
each case, representing different areas of each tumor. 
One section per block was stained with hematoxylin 
and eosin (HE).
Immunohistochemistry
Immunohistochemical studies were carried out 
manually. Sections of representative tumor (USC and 
grade 3 EAC) blocks, 4 microns thick, were stained 
with HE, RFP, WT1, ER, PR, p53 and p16. Low-
grade endometrioid tumors usually can easily be dif-
ferentiated from high-grade tumors by HE stained 
slides. Because of this fact, low-grade EAC cases were 
only stained with FFP to search for the role in endo-
metrial carcinogenesis. Immunohistochemical stain-
ing was carried out by the strepto-avidin biotin meth-
od, using commercially available kits for WT1 (1/50 
Biocare, USA), ER (1/100 Thermo, USA), PR (1/300, 
Neomarker, USA), p53 (1/800 Leica, UK), and p16 
(1/75 Biocare, USA). Anti-RFP antibody (IBL Co, 
Japan) was used as a primary antibody [16]. Briefly, 
deparaffinized sections were treated with methanol 
containing 0.3% H2O2 for 15 min for endogenous 
peroxide blockage. After washing with PBS, blocking 
solution was applied for 5 minutes. All slides received 
pretreatment with citrate for antigen retrieval. Then, 
anti-RFP primary antibody was allowed to react at 
room temperature for 60 minutes in a dilution of 
1 : 750. After washing in PBS, biotinylated antirab-
bit IgG goat secondary antibody was applied for 10 
minutes, followed by horseradish peroxidase-marked 
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strepto-avidin for 10 minutes. Peroxidase was visu-
alized by diaminobenzidine tetrahydrochloride con-
taining 0.3% H2O2. Nuclei were stained with Harris’ 
hematoxylin. Appropriate controls were included for 
this study. The RFP expression was evaluated as pos-
itive when there was nuclear staining.
For statistical analysis, a semi-quantitative scor-
ing method (percentage × intensity) was used, and 
ranged from 0 to 15, as previously described [14]. 
The percentage of staining (scored on a scale of 0-5) 
and staining intensity (scored on a scale of + to 
+++; with 0 = negative, + = mild, ++ = mod-
erate, +++ = severe) were assessed. The percent-
age of staining was scored as follows: 0 = 0%; 1 = 
1-5%; 2 = 6-25%; 3 = 25–50%; 4 = 50-75%; and 
5 = 75-100%. The scoring of immunohistochemis-
try was done using a compositional method (intensity 
× percentage of staining) for all the markers. P16 
and p53 staining was also evaluated in a two-tier sys-
tem where diffuse staining in almost 100% of tumor 
cells was separately noted. Additionally, p16 and p53 
staining was evaluated in a two-tier system where se-
vere staining of cells in more than 95% of the cell 
population categorized group 1 and the others hav-
ing less staining than 95% of the cell population con-
stituted group 2. 
Statistical analyses
For each marker tested, sensitivity and specific-
ity were calculated. Sensitivity is the probability of 
correctly identifying a true positive result using the 
test, and specificity is the probability of correct-
ly identifying a true negative result. An ideal test 
would have a sensitivity and specificity score of 1, 
i.e. no false positives and no false negatives. Tradi-
tionally, a tradeoff is often needed between the two 
measures and, depending on the case, higher sensi-
tivity or higher specificity may be more desirable. In 
our case, we argued that a higher specificity reduces 
the chance of misclassifying the tumor as EAC, and 
is therefore more useful. Only a p-value of < 0.05 
was considered to be significant. After determining 
the expression of each immunomarker in endome-
trial cancer, we analyzed the value of each marker, 
or any combination of them, in differentiating EAC 
from USC. Sensitivity, specificity, area under the re-
ceiver operating characteristic (ROC) curve, κ statis-
tic for interobserver reproducibility, Kruskal-Wallis 
test, Mann-Whitney U test and Fisher’s exact tests 
were performed for the statistical analyses. IBM SPSS 
Statistics for Windows, Version 20.0 (Armonk, NY: 
IBM Corp, Released 2011) was used for all analyses. 
Results
The patients’ ages ranged from 28 to 89 years 
(mean, 64.79 for grade 1 EAC; 60.91 for grade 3 
EAC; 65.93 for USC; 64.09 for all cases). The study 
consisted of 124 endometrial carcinomas with 60 
grade 3 EAC, 40 USC, and 24 grade 1 EAC. The 
high-grade cases were distributed as 31 stage I (18 
USC, 13 EAC), 12 stage II (6 USC, 6 EAC), 29 stage 
III (19 USC, 10 EAC), and 13 stage IV (11 USC, 
2 EAC) tumors. We were unable to obtain detailed 
clinical information for 15 patients. 
Interobserver reproducibility was evaluated and 
the study was designed according to the consensus 
diagnosis. A total of 100 high-grade endometrial tu-
mor cases (60 cases of grade 3 EAC and 40 cases of 
USC) were reevaluated. As mentioned earlier, all 
slides were evaluated independently by five pathol-
ogists and the general agreement between the ob-
servers was evaluated. The pathologists categorized 
the tumors as EAC and USC. The κ values were 
0.737 and 0.727 for EAC and USC, respectively 
(p < 0.001). Overall agreement was 0.713 (p < 0.001). 
The distribution of p16, p53, WT1, ER, PR and 
RFP expression scores according to the diagnosis is 
summarized in Table I. The RFP scores in each histo-
logic type were compared: the mean RFP score was 
1.54 in grade 1 EAC, 4.31 in grade 3 EAC and 6.31 
Table I. Immunohistochemical markers’ scores (p16, PR, ER, RFP, p53, WT-1) according to tumor types
tumOr type rfp ScOre p16 ScOre pr ScOre Wt-1 ScOre p53 ScOre er ScOre
EAC 
grade 1
Number of cases 
mean (median)
24
1.54 (1)
NA
NA
NA
NA
NA
NA
NA
NA
NA
EAC 
grade 3
Number of cases 
mean (median)
35 
4.31 (4)
33 
10.82 (12)
36
5.67 (1)
34
2.21 (1)
36
6.22 (5)
37
5.81 (4)
USC Number of cases 
mean (median)
57
6.31 (6)
57
13.32 (15)
56
3.45 (1)
55
3.11 (1)
57
11.49 (15)
57
4.81 (1)
TOTAL Number of cases 
mean (median)
92
5.45 (4)
90
12.40 (15)
92
4.32 (1)
89
2.76 (1)
93
9.45 (12)
94
5.20 (1)
*The number of cases differs because some cases cannot be evaluated as the result of technical problems such as sloughing of tissue
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in USC (p < 0.001). Overall, RFP scores were high-
er in both USC and grade 3 EAC cases (p > 0.05), 
whereas they were significantly lower in grade 1 EAC 
(p < 0.05) (Table I).
We evaluated the sensitivity and specificity of the 
immunohistochemical markers for differentiating 
EAC and USC (Table II). We found that p16 and 
p53 staining patterns can differentiate between high-
grade EAC and USC. A discrimination score was 
obtained for p16 and p53, which was found to be 
statistically significant (p = 0.003 and p < 0.001, 
respectively). 
We examined the utility of the markers in de-
termining the tumor types. According to the ROC 
curves predicting high-grade EAC and USC using 
immunomarkers, p53 and p16 were the most useful 
markers for differentiating/discriminating the differ-
ent histologic types (Table III, Figs. 1 and 2).
Note that in Fig. 1, for p16, p53, RFP and WT-1 
markers, higher test results indicate high-grade en-
dometrial tumors, whereas for PR and ER markers 
lower test results indicate high-grade endometrial tu-
mors. Therefore, when we include all markers in the 
same figure, the ROC curves for PR and ER remain 
under the reference line (the line that indicates there 
is no discrimination).
Statistically, diffuse p16 and p53 staining emerged 
as the most sensitive (74% and 74%, respectively) 
and specific (88% and 92%, respectively) markers for 
the differentiation of USC from grade 3 EAC (p < 
0.001). ER, PR, WT-1 and RFP did not reach sta-
tistical significance in the subtyping of high-grade 
tumors, whereas the RFP score was found to be sig-
nificantly higher in grade 3 EAC than in grade 1 
(p < 0.001). 
The RFP score was found to be significantly higher 
in grade 3 EAC and USC. The area under the ROC 
curve for USC and grade 3 EAC was 0.597 and was 
not found to be statistically significant. However, 
the ROC analysis result was 0.776 for serous versus 
Table II. Sensitivity and specificity of immunohistochemical markers differentiating high-grade endometrial tumors 
ScOre BeSt cut-Off SenSitivity Specificity rOc p value
p16 13.5 0.8 0.571 0.684 0.003
p16 diffuse 1.5 0.69 0.83 0.765 < 0.001
p53 13.5 0.69 0.84 0.745 < 0.001
p53 diffuse 13.5 0.84 0.62 0.735 < 0.001
WT1 0.588 0.163
ER 0.558 0.339
PR 0.598 0.113
RFP 0.618 0.058
Note that in Table II we did not report a best cut-off for sensitivity and specificity in WT1, ER, PR and RFP markers because the area under the ROC curve is not 
statistically significant for these markers.
Table III. Area under the ROC curve
immunOmarker area under 
the rOc curve
p value
p16 0.682 0.006
WT-1 0.587 0.192
p53 0.774 < 0.001
RFP 0.589 0.185
PR 0.559 0.345
ER 0.543 0.496
Fig. 1. ROC curves for predicting high-grade EAC and 
USC using p53, p16, RFP, WT-1, PR and ER. According 
to the ROC curves, p53 and p16 are statistically significant 
markers for discriminating high-grade EAC (p < 0.001 
and p = 0.006, respectively)
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grade 1 EAC, and 0.44 for grade 3 EAC versus grade 
1 EAC (p < 0.001 and p = 0.002, respectively). Dif-
ferent RFP expression patterns can be seen in Fig. 3.
Discussion
Differentiating EAC from USC and CCC is im-
portant for patient treatment and prognosis. It is also 
imperative to confirm an accurate diagnosis, not only 
on hysterectomy specimens but also on biopsy/curet-
ting specimens, in order to plan treatment, which in 
turn might have an impact on patient management 
intraoperatively. Although molecular features of en-
dometrial cancers may shed light on the classification 
of high-grade endometrial cancers [9], we still clas-
sify endometrial cancers conventionally according to 
the morphology of the tumor. Common high-grade 
endometrial carcinomas include grade 3 EAC, USC 
and CCC. Most of the high-grade tumors can be di-
agnosed by their morphological features and classi-
fied on the basis of histopathology. However, further 
evaluation is needed for tumors that cause diagnostic 
confusion.
In our previous study, we observed that RFP was 
expressed in all of the ovarian serous carcinoma and 
USC, whereas it was negative in EAC type endome-
trial tumors, endometrial intraepithelial neoplasia, 
and benign endometrial polyps [14]. In our previ-
ous study, although all the EAC were low grade, we 
hypothesized that RFP could be used as a marker 
Fig. 2. Immunohistochemical features of p16 and p53 in high-grade EAC and USC. A) p16 in EAC; B) p53 in EAC; 
C) p16 in USC and D) p53 in USC
A B
C D
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to detect USC in difficult cases that exhibit ambig-
uous features. In addition, RFP was reported to be 
involved in cancer cell migration in endometrial tu-
mors [15]. In that same study, immunohistochemical 
expression of RFP was shown to be associated with 
poor prognosis, such as overall survival and progres-
sion-free survival. In the current study, we examined 
ER, PR, p16, p53, WT-1, and RFP expression in 
endometrial tumors. These immunohistochemical 
markers, except RFP, which is not widely used in clin-
ical practice, are well-known adjunct markers in aid-
ing diagnosis in high-grade endometrial tumors [17, 
18]. We observed that RFP expression is associated 
both with high-grade EAC and with USC. Because 
of the similar expression profile of RFP in high-grade 
carcinomas, this marker cannot be used to differen-
tiate between high-grade EAC and USC. The role of 
RFP in the carcinogenesis of high-grade endometrial 
tumors will be a subject of future research projects.
A panel of markers has been used and reported in 
the literature as being useful in the differential di-
agnosis of high-grade endometrial tumors, especially 
when the morphological features are not characteris-
tic. Aberrant p53 expression supports the diagnosis 
of USC. However, it should be kept in mind that dis-
cordant staining patterns can be seen [17]. A small 
number of grade 2 and 3 EAC overexpress p53, but 
mainly the expression is focal and patchy. p16 expres-
sion is diffuse and strong in USC, whereas staining is 
absent or scattered in grade 3 EAC [19]. 
When we compared the usefulness of the immuno-
histochemical markers listed above for distinguishing 
USC from high-grade EAC, p16 and p53 emerged 
as the most valuable markers in our study. Consis-
tent with other studies in the literature, not only the 
percentage of staining but also the staining intensity 
is important for this differentiation. In USC, almost 
all the neoplastic cells stain strongly with both p16 
and p53. Also, deadly negative p53 staining supports 
the USC diagnosis. Another interesting finding was 
that p53 and p16 were the most sensitive and specif-
ic markers for differentiating USC from high-grade 
EAC in this study group. As our study results imply, 
diffuse (almost all neoplastic cells), strong p53 (or 
deadly negative) and p16 staining are most consis-
tent with USC rather than with high-grade EAC. 
WT-1 is commonly expressed in ovarian serous tu-
mors and accepted as a diagnostic marker for ovarian 
serous carcinoma. In a previous study, a diverse cor-
relation between WT-1 expression and disease-free 
survival in USC was noted by the authors [20]. In 
our current study, there were a few EAC and USC 
cases staining strongly and diffusely with WT-1, 
even though most of the endometrial EAC and USC 
stained poorly or negatively with WT-1. 
In our study, there was substantial agreement in 
the diagnosis of USC and high-grade EAC. However, 
in one published series evaluating the interobserver 
and intraobserver agreement, there was a poor con-
cordance rate in differentiating high-grade endome-
trial cancer [10]. In that study, three experienced gy-
necologic pathologists evaluated the slides from 59 
high-grade endometrial cancer specimens, and a con-
sensus diagnosis was made in only 31 of 59 cases. In 
another study, the authors examined the reproduc-
ibility of the high-grade endometrial cancer diagno-
sis and used a combination of immunohistochemical 
markers for a consensus diagnosis. In that study, 
moderate (k: 0.575) interobserver reproducibility 
was observed, and the authors suggested using p53, 
Fig. 3. RFP staining in A) high-grade USC and B) low-grade EAC
A B
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ER and p16 to distinguish USC from grade 3 EAC. 
Non-informatively, a triple positive immunoprofile 
was noted both in grade 3 EAC and USC in simi-
lar frequencies. In these situations, the authors again 
suggested use of additional markers [11]. Hoang et 
al. reported average k values (k: 0.55; range: 0.30-
0.67) for high-grade endometrial cancer in 36 cases. 
After immunohistochemical evaluation it increased 
to 0.68 (range: 0.65-0.81) [21].
In our study, we obtained high interobserver 
agreement among the participating gynecopatholo-
gists. It is probably due to the selection of limited 
cases (only USC and high-grade EAC cases were in-
cluded, while CCC and undifferentiated carcinomas 
were excluded) in the study. Distinguishing between 
EAC and USC is not difficult when the classical histo-
pathological features of each tumor are detected. As 
our study results supported, in cases where diagnostic 
disagreements arise, immunohistochemical markers 
will be helpful. Along with conventional markers, 
new promising markers such as PTEN and MLH1 
proteins, which were intensely positive in USC but 
not in EAC, may also be helpful [22].
In summary, there are still unresolved problems 
in the differential diagnosis of highgrade endome-
trial tumors, one of which is the low reproducibili-
ty of morphologic diagnosis. This problem is more 
common in endometrial carcinomas than in ovarian 
carcinomas. We do not yet fully understand tumor 
progression in endometrial cancer, and have limited 
data for carcinogenesis [17]. In this cohort of high-
grade EAC and USC, we were able to reach substan-
tial interobserver agreement and showed that diffuse 
p53 and p16 staining offers the most sensitive and 
specific immunomarkers for differentiating these two 
high-grade tumors. In addition, we confirmed the se-
lective expression of RFP in high-grade endometrial 
carcinoma compared to grade 1 EAC.
The authors declare no conflict of interest.
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